Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (7): 634-639.DOI: 10.3969/j.issn.1673-8640.2024.07.003
Previous Articles Next Articles
LIU Yi1, SU Xiaoming2, WANG Yuanyuan2(), JU Tao3
Received:
2023-02-10
Revised:
2024-04-08
Online:
2024-07-30
Published:
2024-07-31
CLC Number:
LIU Yi, SU Xiaoming, WANG Yuanyuan, JU Tao. Roles of serum L-Arg and IL-4 levels in predicting recurrent ischemic stroke in patients with symptomatic carotid artery stenosis[J]. Laboratory Medicine, 2024, 39(7): 634-639.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.07.003
组别 | 例数 | 高血压史/ [例(%)] | 糖尿病史/ [例(%)] | 高血脂史/ [例(%)] | 冠心病史/ [例(%)] | 吸烟史/ [例(%)] | 重度血管狭窄/ [例(%)] | 易损斑块/ [例(%)] |
---|---|---|---|---|---|---|---|---|
未再发组 | 161 | 95(59.00) | 36(22.36) | 25(15.52) | 35(21.73) | 47(29.19) | 54(33.54) | 60(37.26) |
再发组 | 35 | 30(85.71) | 13(37.14) | 17(48.57) | 10(28.57) | 14(40.00) | 26(74.28) | 28(80.00) |
χ2值 | 8.877 | 3.351 | 18.645 | 0.759 | 1.567 | 19.759 | 21.221 | |
P值 | 0.003 | 0.067 | <0.001 | 0.384 | 0.211 | <0.001 | <0.001 |
组别 | 例数 | 高血压史/ [例(%)] | 糖尿病史/ [例(%)] | 高血脂史/ [例(%)] | 冠心病史/ [例(%)] | 吸烟史/ [例(%)] | 重度血管狭窄/ [例(%)] | 易损斑块/ [例(%)] |
---|---|---|---|---|---|---|---|---|
未再发组 | 161 | 95(59.00) | 36(22.36) | 25(15.52) | 35(21.73) | 47(29.19) | 54(33.54) | 60(37.26) |
再发组 | 35 | 30(85.71) | 13(37.14) | 17(48.57) | 10(28.57) | 14(40.00) | 26(74.28) | 28(80.00) |
χ2值 | 8.877 | 3.351 | 18.645 | 0.759 | 1.567 | 19.759 | 21.221 | |
P值 | 0.003 | 0.067 | <0.001 | 0.384 | 0.211 | <0.001 | <0.001 |
组别 | 例数 | 基线强度/dB | 峰值强度/dB | AUCTC/(dB·s﹣1) | 颈动脉狭窄率/% |
---|---|---|---|---|---|
未再发组 | 161 | 2.52±0.63 | 11.82±3.70 | 422.21±211.00 | 67.59±9.68 |
再发组 | 35 | 2.59±0.19 | 22.34±9.16 | 704.50±285.05 | 77.52±10.17 |
t值 | 0.670 | 11.046 | 6.705 | 5.275 | |
P值 | 0.504 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 基线强度/dB | 峰值强度/dB | AUCTC/(dB·s﹣1) | 颈动脉狭窄率/% |
---|---|---|---|---|---|
未再发组 | 161 | 2.52±0.63 | 11.82±3.70 | 422.21±211.00 | 67.59±9.68 |
再发组 | 35 | 2.59±0.19 | 22.34±9.16 | 704.50±285.05 | 77.52±10.17 |
t值 | 0.670 | 11.046 | 6.705 | 5.275 | |
P值 | 0.504 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | L-Arg/ (μmol·L-1) | IL-4/ (pg·mL-1) |
---|---|---|---|
未再发组 | 161 | 63.25±21.71 | 110.54±30.82 |
再发组 | 35 | 38.95±18.69 | 76.89±35.09 |
t值 | 6.141 | 5.707 | |
P值 | <0.001 | <0.001 |
组别 | 例数 | L-Arg/ (μmol·L-1) | IL-4/ (pg·mL-1) |
---|---|---|---|
未再发组 | 161 | 63.25±21.71 | 110.54±30.82 |
再发组 | 35 | 38.95±18.69 | 76.89±35.09 |
t值 | 6.141 | 5.707 | |
P值 | <0.001 | <0.001 |
项目 | 峰值强度 | AUCTC | 颈动脉狭窄率 |
---|---|---|---|
L-Arg | |||
r值 | -0.438 | -0.284 | -0.283 |
P值 | <0.001 | <0.001 | <0.001 |
IL-4 | |||
r值 | -0.329 | -0.254 | -0.159 |
P值 | 0.027 | <0.001 | 0.026 |
项目 | 峰值强度 | AUCTC | 颈动脉狭窄率 |
---|---|---|---|
L-Arg | |||
r值 | -0.438 | -0.284 | -0.283 |
P值 | <0.001 | <0.001 | <0.001 |
IL-4 | |||
r值 | -0.329 | -0.254 | -0.159 |
P值 | 0.027 | <0.001 | 0.026 |
自变量 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI②) |
---|---|---|---|---|---|
L-Arg | -0.039 | 0.019 | 4.507 | 0.034 | 0.961(0.927~0.997) |
IL-4 | -0.022 | 0.011 | 4.283 | 0.038 | 0.978(0.957~0.999) |
峰值强度 | 0.207 | 0.058 | 12.630 | 0.000 | 1.230(1.097~1.378) |
AUCTC | 0.003 | 0.001 | 3.977 | 0.046 | 1.003(1.000~1.006) |
易损斑块 | 3.010 | 1.036 | 8.438 | 0.004 | 20.295(2.662~154.718) |
血管重度狭窄 | 2.752 | 0.934 | 8.681 | 0.003 | 15.675(2.513~97.784) |
高血压史 | 1.296 | 0.912 | 2.019 | 0.155 | 3.654(0.612~21.829) |
高血脂 | 2.112 | 0.857 | 6.078 | 0.014 | 8.267(1.542~44.318) |
年龄 | 0.075 | 0.067 | 1.272 | 0.259 | 1.078(0.946~1.229) |
自变量 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI②) |
---|---|---|---|---|---|
L-Arg | -0.039 | 0.019 | 4.507 | 0.034 | 0.961(0.927~0.997) |
IL-4 | -0.022 | 0.011 | 4.283 | 0.038 | 0.978(0.957~0.999) |
峰值强度 | 0.207 | 0.058 | 12.630 | 0.000 | 1.230(1.097~1.378) |
AUCTC | 0.003 | 0.001 | 3.977 | 0.046 | 1.003(1.000~1.006) |
易损斑块 | 3.010 | 1.036 | 8.438 | 0.004 | 20.295(2.662~154.718) |
血管重度狭窄 | 2.752 | 0.934 | 8.681 | 0.003 | 15.675(2.513~97.784) |
高血压史 | 1.296 | 0.912 | 2.019 | 0.155 | 3.654(0.612~21.829) |
高血脂 | 2.112 | 0.857 | 6.078 | 0.014 | 8.267(1.542~44.318) |
年龄 | 0.075 | 0.067 | 1.272 | 0.259 | 1.078(0.946~1.229) |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% |
---|---|---|---|---|
L-Arg | 0.803(0.717~0.888) | 35.96 μmol·L-1 | 84.50 | 74.30 |
IL-4 | 0.760(0.680~0.841) | 94.92 pg·mL-1 | 83.20 | 71.00 |
联合检测 | 0.845(0.763~0.926) | 0.76 | 77.10 | 82.60 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% |
---|---|---|---|---|
L-Arg | 0.803(0.717~0.888) | 35.96 μmol·L-1 | 84.50 | 74.30 |
IL-4 | 0.760(0.680~0.841) | 94.92 pg·mL-1 | 83.20 | 71.00 |
联合检测 | 0.845(0.763~0.926) | 0.76 | 77.10 | 82.60 |
组别 | 例数 | 易损斑块/ [例(%)] | 稳定斑块/ [例(%)] |
---|---|---|---|
L-Arg降低组 | 51 | 36(70.59) | 15(29.41) |
L-Arg未降低组 | 145 | 52(35.86) | 93(64.14) |
χ2值 | 18.391 | ||
P值 | <0.001 |
组别 | 例数 | 易损斑块/ [例(%)] | 稳定斑块/ [例(%)] |
---|---|---|---|
L-Arg降低组 | 51 | 36(70.59) | 15(29.41) |
L-Arg未降低组 | 145 | 52(35.86) | 93(64.14) |
χ2值 | 18.391 | ||
P值 | <0.001 |
组别 | 例数 | 易损斑块/ [例(%)] | 稳定斑块/ [例(%)] |
---|---|---|---|
IL-4降低组 | 49 | 33(67.35) | 16(32.65) |
IL-4未降低组 | 147 | 55(37.41) | 92(62.59) |
χ2值 | 13.309 | ||
P值 | <0.001 |
组别 | 例数 | 易损斑块/ [例(%)] | 稳定斑块/ [例(%)] |
---|---|---|---|
IL-4降低组 | 49 | 33(67.35) | 16(32.65) |
IL-4未降低组 | 147 | 55(37.41) | 92(62.59) |
χ2值 | 13.309 | ||
P值 | <0.001 |
[1] | 严可, 杨燕玲, 张露, 等. Essen卒中风险评分对首发缺血性卒中患者第一年复发风险的预测效果分析[J]. 中国脑血管病杂志, 2020, 17(11):648-654. |
[2] | 钟根龙, 陈伟康, 项琳, 等. 颅脑灌注缺损对症状性颈动脉狭窄患者缺血性脑卒中复发风险的影响[J]. 心脑血管病防治, 2022, 22(1): 83-86. |
[3] | ZHANG Y, WANG W, FANG Q. Clinical study of stent forming for symptomatic internal carotid artery stenosis[J]. Medicine(Baltimore), 2020, 99(25):e20637. |
[4] | MESSAS E, GOUDOT G, HALLIDAY A, et al. Management of carotid stenosis for primary and secondary prevention of stroke:state-of-the-art 2020:a critical review[J]. Eur Heart J Suppl, 2020, 22(Suppl M):M35-M42. |
[5] |
KOTAGALE N R, TAKSANDE B G, INAMDAR N N. Neuroprotective offerings by agmatine[J]. Neurotoxicology, 2019, 73:228-245.
DOI PMID |
[6] | 王启荣, 何小明, 卢祖能, 等. Th2细胞及其细胞因子IL-4对缺血性脑卒中患者病情发展及预后的影响[J]. 广西医科大学学报, 2018, 35(1):18-22. |
[7] | 中华医学会外科学分会血管外科学组. 颈动脉狭窄诊治指南[J]. 中国血管外科杂志(电子版), 2017, 9(3):169-175. |
[8] | 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 急性缺血性脑卒中诊疗指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682. |
[9] | 张娟, 张春梅, 陈伟男. 急性脑梗死患者外周血中性粒细胞/淋巴细胞比值与颈动脉易损斑块的关系[J]. 中国现代医学杂志, 2021, 31(2):67-71. |
[10] | 陈亮, 黄芸, 严诚, 等. 血浆Hcy水平与缺血性脑卒中患者颈动脉狭窄程度的相关性研究[J]. 中西医结合心血管病电子杂志, 2021, 9(6):84-87. |
[11] | 王华, 李天天. 常规超声、超微血管成像和超声造影诊断颈动脉狭窄的对比研究[J]. 中国现代医学杂志, 2021, 31(5):62-67. |
[12] |
黄语悠, 房亚兰, 师文娟, 等. 一氧化氮合酶抑制剂N-硝基-L-精氨酸甲酯对局灶性脑缺血再灌注大鼠缺血半暗带区细胞自噬的影响[J]. 首都医科大学学报, 2018, 39(3):355-359.
DOI |
[13] | 冯程程, 朱瑞霞, 何志义. 脑梗死患者血清 miR-181c,miR-21水平与颈动脉狭窄及其不良预后的相关性预测[J]. 西部医学, 2022, 34(6):851-855. |
[14] | CARBALLO-PERICH L, PUIGORIOL-ILLAMOLA D, BASHIR S, et al. Clinical parameters and epigenetic biomarkers of plaque vulnerability in patients with carotid stenosis[J]. Int J Mol Sci, 2022, 23(9):5149. |
[15] | VELTKAMP R, PEARCE L A, KOROMPOKI E, et al. Characteristics of recurrent ischemic stroke after embolic stroke of undetermined source:secondary analysis of a randomized clinical trial[J]. JAMA Neurol, 2020, 77(10):1233-1240. |
[16] | 臧琳, 樊露, 仇建婷, 等. 症状性颈内动脉狭窄患者脑卒中复发影响因素的研究进展[J]. 中华老年心脑血管病杂志, 2020, 22(6):668-670. |
[17] | 许志荣, 徐晚虹, 李拾林, 等. 弹性成像联合超声造影定量评估颈动脉低回声斑块与脑梗死再发的关系[J]. 中国超声医学杂志, 2021, 37(1):15-17. |
[18] | BLADOWSKI M, GAWRYS J, GAJECKI D, et al. Role of the platelets and nitric oxide biotransformation in ischemic stroke:a translative review from bench to bedside[J]. Oxid Med Cell Longev, 2020, 2020:2979260. |
[19] |
张红, 张正红, 张陈珊, 等. L-精氨酸与α1-肾上腺素能受体在肾功能调节中的作用[J]. 中国医学科学院学报, 2020, 42(6):815-819.
DOI |
[20] | MOLNAR T, CSUKA D, PUSCH G, et al. Associations between serum L-arginine and ficolins in the early phase of acute ischemic stroke:a pilot study[J]. J Stroke Cerebrovasc Dis, 2020, 29(8):104951. |
[21] | BIMA C, PARASILITI-CAPRINO M, RUMBOLO F, et al. Asymmetric and symmetric dimethylarginine as markers of endothelial dysfunction in cerebrovascular disease:a prospective study[J]. Nutr Metab Cardiovasc Dis, 2024, 13:S0939-4753(24)00117-0. |
[22] | 刘秋平, 张雪竹. 小胶质细胞与T细胞的交互作用对缺血性卒中后脑损伤的影响[J]. 国际脑血管病杂志, 2019, 27(3):223-229. |
[23] | 王启荣, 何小明, 卢祖能, 等. Th2细胞及其细胞因子IL-4对缺血性脑卒中患者病情发展及预后的影响[J]. 广西医科大学学报, 2018, 35(1):18-22. |
[24] |
王李润, 王立斯. 天疱疮患者血清 IL-10、sIL-2R、IFN-γ 水平与病情严重程度的相关性[J]. 检验医学, 2022, 37(2):196-197.
DOI |
[25] |
HOVHANNESYAN R A, HOVHANNISYAN I G. Platelet aggregation and interleukins indicators impacting the outcomes of ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2019, 28(7):2038-2044.
DOI PMID |
[26] | 潘赫男, 李俐涛. 小胶质细胞与缺血性脑卒中研究进展[J]. 脑与神经疾病杂志, 2020, 28(1):45-47. |
[27] | 冯涛. 瑞舒伐他汀对急性脑缺血再灌注大鼠脑含水量及海马区MG的影响[J]. 中风与神经疾病杂志, 2018, 35(3):216-219. |
[28] | TING S M, ZHAO X, ZHENG X, et al. Excitatory pathway engaging glutamate,calcineurin,and NFAT upregulates IL-4 in ischemic neurons to polarize microglia[J]. J Cereb Blood Flow Metab, 2020, 40(3):513-527. |
[1] | KANG Yi, ZHANG Qiaoling, SHI Yanfang, WANG Yujia, CHEN Xiaodan, PENG Youqun. Roles of serum miR-181b and miR-144 expressions in early neurological deterioration in patients with acute ischemic stroke [J]. Laboratory Medicine, 2025, 40(1): 73-78. |
[2] | DING Jing, ZHANG Chunling, WANG Xiaorui, LI Huidan, WANG Hongling, LIU Weiling, LIN Lihui, LI Li. Laboratory diagnosis and prognostic factor analysis of core binding factor-related acute myeloid leukemia [J]. Laboratory Medicine, 2024, 39(7): 673-681. |
[3] | GU Liangliang, WANG Jianfeng, QIAO Xin, ZHANG Baochao, FU Guohui. Correlation between serum LRG1 level and cognitive impairment and recurrence in patients with acute ischemic stroke [J]. Laboratory Medicine, 2024, 39(5): 443-448. |
[4] | SHEN Zhan, BIAN Xiaobo, HUANG Ying, WANG Siyang, SHEN Tingting, ZHANG Xian, SONG Yunxiao, XIE Lianhong. Stroke recurrence prediction model based on machine learning algorithms using routine blood test [J]. Laboratory Medicine, 2024, 39(12): 1190-1195. |
[5] | WU Ying, ZHANG Lihong, GAO Yin. Predictive value of high-density lipoprotein cholesterol on the risk of cerebral ischemic stroke in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2023, 38(11): 1052-1056. |
[6] | ZHU Qian, ZHU Lifang, MA Caiyun, YAO Jie. Relation of serum miR-140-5p and PGC-1α mRNA expression with vascular cognitive impairment in acute ischemic stroke patients [J]. Laboratory Medicine, 2023, 38(11): 1069-1074. |
[7] | LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422. |
[8] | ZHENG Yu, CHEN Jin. Correlation between serum follistatin and clinicopathological characteristics and prognosis of patients with differentiated thyroid cancer [J]. Laboratory Medicine, 2022, 37(11): 1066-1070. |
[9] | MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46. |
[10] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
[11] | LI Jinyi, LI Chunlei, JIA Yonglin, JIA Dongpei. Plasma ADAMTS-7 level and its relationship with prognosis in patients with acute ischemic stroke [J]. Laboratory Medicine, 2021, 36(10): 1033-1038. |
[12] | CHEN Yabin, CAI Hehui, ZHANG Jianming, SU Yongfa, ZHANG Zhishan. Relationship between plasma small dense low-density lipoprotein and ischemic stroke [J]. Laboratory Medicine, 2020, 35(5): 409-413. |
[13] | JIN Fangfang, JIN Zizheng, LIU Ning, LOU Jinli. Changes of CD3bright T lymphocytes in patients with hepatocellular carcinoma before and after recurrence [J]. Laboratory Medicine, 2020, 35(3): 209-213. |
[14] | DONG Huan, LIU Xiaoyi, CAI Yanqing, CHEN Xinliang, WANG Xianjing. Difference of the expressions of ER,VEGF and TGF-β1 between multiple EP and single EP patients and their prognosis analysis [J]. Laboratory Medicine, 2019, 34(5): 415-420. |
[15] | YI Qingqing, YANG Rong, LIANG Dongyu, CHANG Qing. Relationship between P53 expression and the recurrence,metastasis and prognosis of breast cancer patients [J]. Laboratory Medicine, 2019, 34(12): 1107-1110. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||